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Purpose: Epithelial ovarian carcinogenesis may occur de novo on the surface of ovarian
mesothelial epithelial cells or from cells originating in other organs. Foreign Mu¨llerian cell
intrusion into the ovarian environment has been hypothesized to explain the latter scenario. In
this study, MALDI MS profiling technology was used to provide molecular insights regarding
these potentially different mechanisms.
Experimental design: UsingMALDIMS profiling, themolecular disease signatures were estab-
lished in their anatomical context. MALDI MS profiling was used on serous and endometrioid
cancer biopsies to investigate cases of epithelial ovarian cancer. We then applied bioinformatic
methods and identification strategies on the LC-MS/MS analyses of extracts from digested
formalin-fixed, paraffin-embedded tissues. Extracts from selected regions (i.e. serous ovarian
adenocarcinoma, fallopian tube serous adenocarcinoma, endometrioid ovarian cancer, benign
endometrium, and benign ovarian tissues) were performed, and peptide digests were subjected
to LC-MS/MS analysis.
Results: Comparison of the proteins identified from benign endometrium or three ovarian
cancer types (i.e. serous ovarian adenocarcinoma, endometrioid ovarian adenocarcinoma, and
serous fallopian tube adenocarcinoma) provided new evidence of a possible correlation between
the fallopian tubes and serous ovarian adenocarcinoma.Here,we propose aworkflowconsisting
of the comparison of multiple tissues in their anatomical context in an individual patient.
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Conclusion and clinical relevance: The present study provides new insights into the molecular
similarities between these two tissues and an assessment of highly specific markers for an
individualized patient diagnosis and care.
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1 Introduction
The origin of epithelial ovarian cancers (EOC) is a critical clin-
ical issue. Currently, patients with a mutation in the BRCA
gene, who are at higher risk for EOC, are surgically treated
with a prophylactic bilateral salpingo-oophorectomy, which is
the complete removal of the ovary and fallopian tubes. This
procedure decreases the patients’ quality of life because the
total removal of the ovaries inducesmenopause, consequently
making those women infertile.
There are two hypotheses for the origin of EOCs, i.e. the
intrinsic and extrinsic [1, 2]. Ovarian cancer may develop de
novo from the mesothelial epithelial cells located on the sur-
face of the ovary or from cells originating in other organs [1–3]
(Fig. 1). If the Mu¨llerian origin of serous ovarian cancer the-
ory is valid, then the surgical removal of the junction of the
fallopian tube and the ovary would reduce the risk of devel-
oping serous ovarian cancers to the same extent as a bilateral
salpingo-oophorectomy. A fimbriectomy, which consists of
Figure 1. Recapitulation of the Mu¨llerian origin of ovarian cancer
type theories.Neoplastic processes may originate in Mu¨llerian-
related tissues and spread to the ovaries via postovulation scars
or can directly evolve from benign cells. For endometrioid tis-
sues, retrograde menstruation may play a role in disseminating
cells from the endometrium to the ovaries. In serous cases, cells
may come from the STICs evolving at the junctions between the
fallopian tubes and the ovaries. Each tissue subtype and evolu-
tion grade is represented by a color that corresponds with the
colors used for the PCA spectra spots in the following figures.
the removal of the fallopian tube and the junction between
the fimbria and the ovary, has been proposed by some sur-
geons [4] for patients who have BRCA mutations. The theory
of de novo EOC appearance is supported by HOX gene ex-
pression, which regulates the Mu¨llerian duct differentiation
in epithelial ovarian cancer, but not in normal ovarian sur-
face epithelium. The ectopic expression of the HOX genes
in mouse ovarian surface epithelium leads to the develop-
ment of tumors that resemble EOC. In this scenario, differ-
ent HOX genes give rise to distinct EOC histological subtypes
(i.e. Hoxa9 for serous, Hoxa10 for endometrioid and Hoxa11
for mucinous cancer [1]). However, several studies have rein-
forced the second and newer theory, and the principal types
of ovarian cancer tissues share similar characteristics with
normal Mu¨llerian-type tissues. Serous cancer tissue strongly
resembles fallopian tube tissue, endometrioid tissue is sim-
ilar to endometrial tissue, and mucinous tissue resembles
intestinal tissue [1–3]. Recent studies on serous adenocarci-
noma, the most common type of ovarian cancer, have shown
that 80% of these adenocarcinomas are associated with in situ
cancerous lesions of the tubal epithelium called “serous tubal
intraepithelial carcinoma” (STIC), which may be the source
of ovarian cancer [5–12]. Moreover, genomic signatures that
may be associated with STICs, such as mutations in the p53
gene, have been observed [13–19]. Additional studies have
identified other common serous ovarian and fallopian tube
cancer signatures, indicating that some Mu¨llerian markers,
such as PAX8, are commonly found in fallopian tubes and
ovarian cancers and not in the mesothelial epithelium of the
ovary. Further studies have shown that mesothelial markers
such as calretinin are absent [17].
The origin of serous ovarian cancer is still under debate,
but evidence elucidating the molecular nature of the tissues
may be provided by mass spectrometric strategies. In the
early 1990s, MALDI MS profiling, which consists of the di-
rect molecular analysis of hundreds of biological compounds
in tissues, was proposed [20]. Since the beginning of the
last decade, many institutions have invested in molecular
histological screening [20–25], including that of ovarian can-
cer samples [22, 25–31]. Thus, MALDI MS molecular pro-
filing is considered a new and important “molecular histol-
ogy” tool. We proposed to investigate the molecular nature
of serous and endometrioid cancers using the novel MALDI
MS profiling technology (Fig. 2A and B). This technology
provides a comparison of the molecular profiles from differ-
ent ovarian cancer tissues with the corresponding reference
tissues.
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Figure 2. (A) The tissue preparation and analysis workflow for MALDI profiling and on-tissue proteomics. The resected organs or tissues
were formalin fixed, paraffin embedded, and sliced with a microtome. The sections were mounted on conductive slides and dewaxed
before antigen retrieval, the matrix was dropped onto the section, and the mass spectrometric analysis was performed on the tissue area.
(B) The corresponding PCA of the tissue with normal and carcinomatous endometrium. The PC1/PC2, PC1/PC3, and PC2/PC3 analyses
are shown, illustrating the best 2D-space separation of the ions. (C) After PCA analysis, the tryptic digests were extracted for the tissue
sections by solvents washes. These digests were submitted to proteomic analyses. The use of specific software allowed us to determine
the proteins’ molecular functions and biological processes. It was also possible to elaborate the interaction networks of the proteins of
interest.
In this present study, we first evaluated the use of MALDI
MS on tissues on endometrioid low-grade ovarian cancer
cases. Using PCA calculations on acquired spectra, we com-
pared the global molecular profiles of the different tissues
involved in the evolution of this pathology, i.e. between the
endometrium and the ovaries.
This first examination allowed us to observe in a handly
view of the global similitudes and dissimilitudes of endome-
trial and ovarian tissues.
The second part of the study is a more extensive anal-
ysis aiming to bring new clues for the tubal origin of
serous ovarian cancer. Indeed, we first evaluated the global
profiles of tubal and ovarian tissues by PCA analyses on
MALDI MS spectra using the same procedure in the first
part.
We then aimed to identify the potential molecular actors
implicated in the close relationship between ovarian serous
cancer tissues and tubal tissues. To do so, we performed a
solvent-based extraction on previously analyzed regions of
interest in the different tissues and conducted LC-Orbitrap
MS analyses. The use of bioinformatics for analyzing the
proteomics information allowed us to depict the common
molecular functions for the cancerization of different organs
and gave us access to the organs’ specific molecular content
(Fig. 2C).
2 Materials and methods
2.1 Materials
CHCA and TFA were obtained from Sigma-Aldrich and used
without further purification. Trypsin was purchased from
Promega. ACN p.a. and methanol p.a. were obtained from
J.T. Baker.
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2.2 Samples
Formalin-fixed, paraffin-embedded (FFPE) tissues were ob-
tained from the CHRU de Lille pathology department. An
institutional review approval (CPP Nord Ouest IV 12/10) was
obtained without requiring informed consent from patients.
The ethical committee considered contacting the patients,
often many years after surgery, to be unnecessary. Our ref-
erence pathologist (O. K.) selected the FFPE blocks that in-
cluded ovarian cancer tissue and tissue from the potential
Mu¨llerian precursor. To avoid interpatient variability, each
figure in the Results section represents tissue from the same
patient. The International Federation of Gynecology and Ob-
stetrics stages for each specimen were determined, and the
results of the histological examinations were recorded. For
the histological imaging prior toMALDI analysis, 4-m-thick
tissue sections were cut from the FFPE whole-mount ovarian
tissue blocks. The sections were placed on indium tin oxide-
coated slides and heated for 60 min at 58C [29]. The tissue
was counterstained with hematoxylin, eosin, and safranin
(HES), dehydrated using a graded ethanol series, and air-
dried for histological examination by our staff pathologist.
The tissues appeared heterogeneous and contained cancer-
ous, hyperplastic, and normal regions, with stromal tissue in
each region [29, 32].
2.3 HES staining
The following procedure was used for the HES staining. The
sections were heated for 5 min, stained with hematoxylin for
3min, rinsedwithwater, washed twice in a solution of 156mL
EtOH (95%), 44 mL H2O, and 80 L HCl, washed in water,
washed in a solution of 0.48 mL NH4OH (35%) and 200 mL
H2O, washed with water for 5 min, washed in ethanol (80%),
colored with eosin for 10 s, washed twice with ethanol (95%),
washed twice with ethanol (100%), stained with safranin
(10 g/L in ethanol (100%)) for 6 min, and then washed twice
in ethanol (100%) and once in xylene for 1 min [29, 33].
2.3.1 Tissue dewaxing
Ovarian FFPE tissues were used for the retrospective studies.
Tissue sections (6m)were generatedusing amicrotomeand
were placed on conductive glass slides coated with indium tin
oxide on one side. The paraffin was removed by submersion
in toluene twice for 5 min followed by a light rehydration in
ethanol baths (100, 96, 70, and 30%) before the slides were
dried in a desiccator at room temperature [29, 33].
2.3.2 Antigen retrieval
FFPE tissues have well-conserved tissue morphology and the
capacity to prevent molecular degradation. Due to methy-
lene bridge formation during conservation, trypsin digestion
is often necessary to retrieve protein information. Because
cross-linking continues over time in FFPE tissue blocks, pro-
tein accessibility becomes increasingly difficult. Enzymatic
cleavage may be affected, which may lead to poor enzymatic
yields. Therefore, it is necessary to establish processes that fa-
cilitate protein access, and many such protocols exist [33,34].
However, the associatedmolecular changes of these so-called
antigen retrieval (AR) processes remain poorly understood.
The most reasonable hypothesis is that AR allows changes in
the conformation of cross-linked proteins and thus facilitates
access to sites within proteins. Due to the variation among
protocols, systematic tests of different AR techniques are re-
quired for an optimized protocol, so several protocols were
tested here. Citric acid AR provides good results with prostate
tissue sections [33]. Citric acid AR protein unmasking was
performed by immersing the slides in 10 mM of citric acid
for 20min at 98C and drying them in a desiccator for 10min.
Prior to enzymatic digestion, the slides were incubated twice
in 10 mM NH4HCO3 to remove the remaining AR solution
and condition the tissue for effective enzyme activity.
2.4 Trypsin digestion and matrix digestion
Ten milliliters in total of a solution containing 40 g/mL
trypsin in 50 mM ammonium bicarbonate was dropped onto
each tissue discrete region of interest using gel loader tips
(the 10 L have been dropped in 5 times using 2 L of solu-
tion). This procedure avoids the drop to spread and thus to
have a mixed up of different cell types. The slides were then
incubated for 4 h at 37C in a customized humidity chamber
(a 10 cm × 15 cm box filled with water to one quarter of the
box height and placed in a 37 incubator). After the trypsin
digestion, 10 L of a 10 mg/mL CHCA solution in aqueous
TFA 0.1%/ACN (3:7) was dropped onto each section [35, 36].
2.5 MALDI MS profiling methodology
The MS profiling approach is presented in Fig. 2A and
B [22, 25]. The first step includes the sectioning and prepara-
tion of tissue using standardmethods. The preservation of tis-
sue integrity while avoiding molecular composition changes
(e.g. enzymatic activation) is of utmost importance. The sec-
ond and third steps are based onMALDI-MS technology. The
second crucial step is the deposition of the matrix onto the
tissue section. The importance of the matrix for mass spectra
quality is well established, and the proper matrix choice is
crucial for a successful MALDI experiment. It is also impor-
tant that the MALDI-MSI matrix does not induce molecular
delocalization across the tissue sample. Such delocalization
must not spread further than the area analyzed by one laser
pulse. The third step is the tissue data acquisition. This step
depends on the mass analyzer and involves optimizing vari-
ous parameters; the acquisition step requires the automation
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of the analytical process. The final step consists of data pro-
cessing via informatics tools.
2.6 Tissue profiling using MALDI
For each tissue, 50 spectra were acquired on spots
homogeneously distributed across the analysis sur-
face. The profiles were acquired using an Ultra-
Flex II MALDI-TOF/TOF instrument (Bruker Daltonics,
Bremen, Germany) equipped with a smart beam laser with
a 200 Hz repetition rate and controlled by FlexControl 2.5
software (Bruker Daltonics). The mass spectra profiles were
acquired in the positive reflection mode in the 500–5500 Da
mass range. One thousand spectra were acquired at each
position using a 200 Hz laser frequency. The images were
recorded and reconstructed using FlexImaging II 2.5 soft-
ware (Bruker Daltonics).
2.7 Statistical data analysis
The data obtained using FlexImaging II 2.5 software (Bruker
Daltonics) were loaded into the ClinProTools v2.5 software
(Bruker Daltonics) to conduct PCA and hierarchical cluster-
ing analysis. After standardization of the data, the unsuper-
vised PCA method was selected. The PC1 and PC2 compo-
nents were found to have the largest variance [33, 37].
2.8 LC-MS/MS Analyses
Trypsin-digested peptides from the FFPE tissue after the anti-
gen retrieval procedureweremanually extracted from specific
tissue regions after PCA. Using a micropipette, specific re-
gions were subjected to 20 successive washes with 100 L of
80% ACN in water. The extract solution was then dried with
a SpeedVac (Savent). The dried peptides were redissolved in
10 L 0.1% TFA. The salts were removed from the solution,
and peptides were concentrated using a solid–phase extrac-
tion procedure with a Millipore ZipTip device in 10 L 80%
ACN elution solution. The solution was dried again using a
SpeedVac, and the dried samples were resuspended in a so-
lution of 5% ACN and 0.1% formic acid. The samples were
separated by online reversed-phase chromatography using a
Thermo Scientific Proxeon Easy-nLC system equipped with a
Proxeon trap column (100 m id × 2 cm, Thermo Scientific)
and a C18 packed-tip column (100 m id × 15 cm, Nikkyo
Technos Co.) [38]. The peptides were separated using an in-
creasing concentration of ACN (5–40% over 110 min) at a
300-nL/min flow rate. The LC eluent was electrosprayed di-
rectly from the analytical column, and a 1.7 kV voltage was
applied via the liquid junction of the nanospray source. The
chromatography system was coupled to a Thermo Scientific
Orbitrap Elite mass spectrometer, which was programed to
acquire in a data-dependent mode. The survey scans were
acquired in the Orbitrap mass analyzer operating at 120 000
(FWHM) resolving power. A mass range of 400–2000 m/z
and a target of 1E6 ions were used for the survey scans. The
precursors observed with an intensity of over 500 counts were
selected “on the fly” for the ion trap CID fragmentation with
an isolation window of 2 amu and a normalized collision en-
ergy of 35%. A target of 5000 ions and a maximum injection
time of 200 ms were used for CID MS2 spectra. The method
was set to analyze the 20 most intense ions from the survey
scan, and a dynamic exclusion was enabled for 20 s. Each
sample has been analyzed three times. The limit of detection
of the instrumentation is 25 000 peptides for an LC-MS/MS
run.
2.9 Analysis
Tandem mass spectra were processed using the Thermo
Scientific Proteome Discoverer software version 1.3. Resul-
tant spectra were matched against the Swiss-Prot R© Human
database (version January 2012) using the SEQUEST R© al-
gorithm. The search was performed by selecting trypsin as
the enzymewith twomissed cleavages allowed. The precursor
mass tolerance was 10 ppm, and the fragmentmass tolerance
was 0.5Da.N-terminal acetylation,methionine oxidation, and
arginine deamination were set as the variable modifications.
Peptide validation was performed using the Percolator algo-
rithm. The peptides were filtered based on a q-value of 0.01,
which corresponds to a 1% false discovery rate.
Only proteins with a score of over 5, which represents
the proteins identified with two or more unique peptides,
were kept for analysis. The relative protein expression was
calculated based on the protein score, which was shown to
be an adequate relative indicator of the relative differential
expression [39, 40]. We compared the acquired results with
an analysis using the Scaffold 3 software [41]. We considered
this method to be quite accurate because it gave similar re-
sults when a quantitative comparison of the different tissues’
proteins relied on spectral counting (data not shown). Gene
ontology analysis was performed using Blast2Go [42]. The
network analysis was performed as follows: The gene names
of identified proteins were used as input to retrieve a net-
work from STRING [43], and this network was then loaded
into Cytoscape 2.8 [44] with relative expression data using Id
mapper. The Reactome FI pluggin was used to select a sub
network of gene ontology terms and NCI database-associated
disease-specific proteins.
3 Results and discussion
The study presented here is composed of two separated parts.
The first one consists in the determination of molecular sig-
natures of tissues from patients afflicted by low-grade en-
dometrioid cancers, using PCA calculations applied to mass
spectra. A solvent extraction has then been performed on the
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ovarian endometrioid cancer tissue, followed by a LCMS/MS
analysis. This analysis has been used to support the second
part of the investigation.
The second part of the investigation consists in the exami-
nation of serous cancer cases. We also present the molecular
profiles of the different tissues. We then focused on one case
to perform an extensive proteomic analysis comparing differ-
ent tissues of interest. This part of the study is devoted to the
finding of clues of the potential tubal origin of ovarian cancer
in this specific clinical case.
Before any analysis, we aimed for the proper selection of
the tissues areas for the molecular comparisons. The meth-
ods presented here allowed us to make the examination of
the molecular content of whole tissue areas without fastid-
ious steps of laser capture microdissections for cell types
selections. In order to avoid any analytical artifacts due to the
analysis of mixed cells types, a first meticulous tissue area
selection have been performed by our reference pathologist
(O. K.). Between any tissues to compare, we aimed to have
the same amount of vessels. For normal tissue tubal, ovarian,
and endometrial tissues, we selected representative regions
of interest of the whole tissue areas, i.e. with the average pro-
portion of stromal and epithelial cells. For cancerous tissue
area selection, we also aimed for the selection of ROI with
average proportion of cancerous epithelia and surrounding
stromal cells.
The cancerous epithelia proportion is the most repre-
sented cell types (80–90%of the cells types), and absolutely ab-
sent from the other tissues which are by almost 100% stomal
cells. We then estimate that the comparison of the cancerous
tissues with normal tissues controls is free of the analytical
artefacts that we could have without a previous selection of
the tissues.
3.1 Part 1: Molecular signature profiling and
proteomic analysis of endometrioid ovarian
cancer tissues
In this first part of the investigation, we selected low-grade
endometrioid tissues in order to test the feasibility of the
PCA procedure to compare molecular profiles of selected tis-
sues of interest. Indeed, we compare the possible similitude
and dissimilitude between normal, cancerous, hyperplastic
endometrium with borderline and cancerous ovaries tissues
that our pathologist found for this case.
Due to the large amount of data acquired using the
MALDI MSI method, data reduction and multivariate anal-
yses were necessary to extract the information of interest.
Among the multivariate methods available, PCA provides
a proven method for automatic feature extraction [26, 33,
37]. Several studies have shown that PCA is a data reduction
method that is useful for MALDI MSI in disease applica-
tions [26, 33, 37, 45, 46]. Therefore, PCA was applied to the
data from several spectral acquisitions. In this bioinformat-
ics spectral data processing, each peak was considered to be
a single dimension, and each group of spectra was consid-
ered to be a multidimensional space. This process reduces
the multidimensional space to two or three dimensions. The
PCA approach provides access to m/z, which demonstrates
differences between or within samples (Fig. 2B). PCA is of-
ten combined with hierarchical clustering (HC) because HC
classifies the mass spectra according to similarities between
their profiles, thus highlighting the regions containing differ-
ing molecular content. In these ways, the different molecular
content profiles may be easily compared among the different
tissue types. As shown in Supporting Information Fig. 1, the
mass spectra observed in normal, borderline, and adenocar-
cinoma ovarian tissues contain a high number of peaks that
appear to present some intensity differences that could not
be precisely quantified manually. PCA analysis thus evalu-
ates the relative intensity of all peaks and provides insight
into differential molecular signatures.
The correlations between each cellular phenotype were
tracked across the m/z detected in each tissue type. The en-
dometrioid cancer origin hypothesis posits that cells from
retrogrademenstruation and endometriosis or endometriotic
cysts reach the ovary, develop in the endometrial tissue and
eventually become cancerous [47]. For each case, the ovar-
ian biopsy was studied concurrently with its respective case-
matched control (i.e. the endometrial tissues). We focused on
the cases whose endometrioid cancers were associated with
endometrial lesions (Fig. 3). HES staining and pathological
analysis were used to study the FFPE sections from different
organs of the same patient. To facilitate the analysis and de-
termine the nature of the tissues, we retained the annotations
added by the pathologist on the tissue section slides.
Two patients were selected because they presented with
ovarian endometrioid and endometrial cancers or hyperpla-
sic lesions. These tissue sections included borderline (BL)
ovarian tissue (in green) and a portion of an adenocarcinoma
(ADK, in blue) (Fig. 3), endometrial tissue (in yellow) (Fig. 3)
and its contralateral normal ovary tissue (in red) (Fig. 3), and
adenocarcinomatous or hyperplastic endometrial tissues (in
purple). Adjacent sections were subjected to the MALDI pro-
filing procedure after citric acid antigen retrieval and trypsin
digestion to unmask the peptide and protein markers. PCA
was performed for each region of interest in the sections; the
data are presented in Fig. 3 for the two patient cases in the A
andB insets. Figure 3A depicts the analysis of the first patient.
Borderline (green) and cancerous (blue) tissue sections were
found in the carcinomatous ovary (Fig. 3A1). These tissues
were compared with normal endometrium (Fig. 3A2), carci-
nomatous endometrium (Fig. 3A2), and normal contralateral
ovary (Fig. 3A3). For this patient, the normal endometrium is
weakly proliferative. In this case, it is easy to distinguish the
spectral profile scatters in the regions of interest, which are
circled in the same colors used to highlight the HES scan sec-
tions. The profiles have a specific order in 2D space, which is
determined by the first PCs (i.e. PC1 and PC2), ranging from
normal endometrial tissue to ovarian carcinoma. Endometrial
carcinoma showed close similaritieswithnormal endometrial
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Figure 3. PCA analysis of the two pa-
tient tissues with endometrioid ovar-
ian cancer. Citric acid AR was applied
to FFPE tissue sections. Ten micro-
liter trypsin droplets were then de-
posited on each tissue region of in-
terest (ROI) and HCCA matrix. Fifty
MALDI/TOF spectra were then acquired
for each region of interest, and the ac-
quired datawere submitted to PCA for a
molecular-based comparison. (A) First
patient case, HES sections (1, 2, 3) and
PCA analyses of normal, adenocarci-
nomatous ovarian tissues, and normal
and adenocarcinomatous endometrial
tissues (4). (B) Second patient case,
HES sections (1, 2) and PCA analyses of
normal, borderline, and adenocarcino-
matous ovarian tissues and normal and
hyperplasic endometrial tissues (3).
tissue (Fig. 3A4). It seems that normal and adenocarcinoma-
tous endometrial tissues share common ions with borderline
ovarian tissue and that borderline ovarian tissue share com-
mon ions with and adenocarcinomatous ovarian tissue. In
this context, the blue arrow represents a possible continuum
in the different molecular contents of the tissues through the
different organs and tissue types.
The inset in Fig. 3B demonstrates the analysis of the sec-
ond endometrioid ovarian cancer case.
In this second case, we found normal, borderline,
and carcinomatous tissues in the ovarian biopsy sections
(Fig. 3B1). Is this case, the patient present an atrophic nor-
mal endometrium. In parallel, this patient presented with an
atypical hyperplastic zone detected near the endometrial tis-
sue that was considered a region of interest (Fig. 3B2). We
found that the PC2–PC3 dimensions indicated a close simil-
itude in the molecular profiles of the normal endometrial
and hyperplastic tissues (Fig. 3B3). In this case, the normal
ovarian molecular profile was different from the preinvasive
and invasive profiles. In the 2D PC space, the molecular-
based profiles of the ovarian borderline and carcinomatous
tissues were placed after the hyperplastic endometrial tis-
sue. From these observations, we suggest that endometrial
hyperplasia may be a latent state for carcinoma progres-
sion. With this global molecular information, we predict
that an endometrial hyperplasic cell may nest in the ovarian
environment and evolve to borderline and lead to a carcino-
matous state.
A solvent extraction of the tryptic peptides from the en-
dometrial adenocarcinoma has then been performed and LC-
MS/MS analyses as mentioned in Section 2. These analyses
have then been used in Part 2 (see Section 3.2).
These results gave us insights in the histological resem-
blance between the tissues involved in endometrioid ovar-
ian cancer progression, and in the possible histological eti-
ology of this type of cancer. We also got a first clue of the
usefulness of this method for the evaluation of this specific
issue.
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3.2 Part 2: Molecular signature profiling of the
tissues and proteomic analysis of serous ovarian
cancer tissues: insights of a possible histological
origin
In this part, we focused on serous ovarian cancers because
the proof of a fallopian tube tissue origin may represent the
most relevant context for further clinical application. Fur-
thermore, serous ovarian cancers represent the most preva-
lent cases. We then applied the MALDI profiling method on
serous ovarian cancer tissues. The results of these analyses
are presented in Fig. 4. The tissue regions of interest are la-
beled pink for the normal fallopian tube, red for normal ovary,
blue for ovarian adenocarcinoma, and turquoise for tubal ade-
nocarcinoma (Fig. 4). Three patient cases were selected. For
a more defined view of the molecular profiles, we added the
hierarchical clustering results of the tissues of interest.
The first patient did not present with any tubal lesions.
Therefore, we aimed to compare the ovarian carcinomatous
regionswith the normal fallopian tube tissue. The tubal origin
of serous ovarian tissue theory also states that a normal cell
from the fallopian tube may evolve into cancer in the ovarian
environment.
The first case is presented in the inset in Fig. 4A. The
PCAs in the first two axes (Fig. 4A2) demonstrated that the
normal fallopian tube and normal ovarian tissues presented
similar molecular profiles that were different from normal
contralateral ovarian tissue. The HC data demonstrated that
the fallopian tube spectra presented an intermediate profile
that was between the ovarian cancer and normal ovarian tis-
sue profiles (Fig. 4A3).
The last patient presented in the inset in Fig. 4B presented
a fallopian tube adenocarcinoma (Fig. 4B1 and B2). The pa-
tient has been diagnosed for the presence of adenocarcino-
matous cells after gynecological examination. A diagnostic
coeliscopy revealed the presence of carcinomatous annexes.
A radical annexectomy has been performed in both the tubal
and the ovarian tissues have been analyzed by the pathologist.
After themicroscopic examination, the pathologist stated that
the tube, that have been taken in totality, presented an inva-
sive adenocarcinomatous proliferation, mostly solid, measur-
ing 8 mm in length on the longer axe. Otherwise the fimbria
was dotted with STIC (Fig. 5). The pathologist clearly stated
that ovarian lesion corresponded to a metastasis of the tubal
adenocarcinoma.
The PCA (Fig. 4B3) shows that ovarian cancer presents
the following order of molecular profiles: normal ovary, nor-
mal fallopian tube, fallopian tube adenocarcinoma, and ovar-
ian serous adenocarcinoma. This observation is in agree-
ment with the molecular origin of ovarian cancer theory. HC
(Fig. 4B4) also confirms the similar characteristics among
ovarian adenocarcinoma and fallopian tube adenocarcinoma
and normal tissues.
These analyses were easy to perform and allowed a quick
survey on the global differential molecular content between
the tissues. Therefore, because the identification of the pro-
teins responsible for molecular differentiation is difficult to
obtain using the MALDI TOF device, we performed an in-
depth analysis of the molecular content of the tissues of in-
terest in the serous ovarian cancer case.
3.2.1 Proteomics analyses of serous ovarian cancer
and tubal cancer tissues
For the proteomics analyses, peptide extractions fromnormal
endometrium and endometrioid ovarian cancer of the case
presented in Fig. 4B were performed, and peptide digests
were then subjected to LC-MS/MS analyses.
Among the identified proteins, those with a score under
5 were removed for subsequent analyses because they were
identified from the MS/MS to have less than two peptides.
We then evaluated the number of common proteins between
the tissues of interest. Each accession number, proteins de-
scription, gene name, and relative score associated with the
selected proteins are reported in Supporting Information
Table 1. The selected tissues are serous ovarian adenocar-
cinoma, fallopian tube serous adenocarcinoma, and benign
ovarian tissues. The Venn diagram presented in Support-
ing Information Fig. 2 illustrates the common identification
between each cancer tissue. The obtained overlapping identi-
fications provide an insight into the molecular similarities of
the tissues. Primarily, the number of specific proteins in the
serous ovarian adenocarcinoma samples appears higher than
any of the other specific proteins, suggesting that many cel-
lular processes involving several proteins may be mandatory
for ovarian cancer progression. The number of proteins in
the two other cancers was similar. We then observed that the
number of common proteins identified between serous EOC
and fallopian tube serous cancerwashigher than that between
the endometrioid EOC type, and the number of common pro-
teins identified between endometrioid EOC and tubal cancer
was more than threefold less than that between serous EOC
and fallopian tube serous cancer. These observations suggest
that serous EOC has a molecular profile that is more sim-
ilar to tubal cancer than any other type of EOC. This point
also supports the ectopic origin of EOC hypothesis. Although
these data provide interesting information regarding the rel-
ative molecular nature of each cancer, this comparison lacks
accuracy because it relied on two patient cases. Thus, the
comparison may be partially influenced by the interpatient
variability.
We then focused on a single patient case of ovarian serous
cancer. We compared the tissues of interest illustrated in
Fig. 4B.
The Venn diagram in Fig. 5A demonstrates the common
identified proteins in benign ovary, serous ovarian cancer,
and serous tubal cancer for the same patient. As illustrated,
more proteins are shared in common between tubal cancer
and serous ovarian cancer than between serous cancer and
the benign ovary. This may suggest that processes impli-
cated in serous related cancers (i.e. ovarian and tubal) require
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Figure 4. PCA analysis of the two patient tissues with serous ovarian cancer. Citric acid AR was applied on FFPE tissue sections. Ten
microliter trypsin droplets were then deposited on each tissue region of interest (ROI) and HCCA matrix. Fifty MALDI/TOF spectra were
then acquired for each region of interest, and the obtained data were submitted to PCA for a molecular-based comparison. (A) First patient
case, HES sections (1), PCA analyses of normal, and adenocarcinomatous ovarian tissues and normal tubal tissue (2), HC of spectra (3). (B)
Second patient case, HES sections (1, 2) and PCA analyses of normal and adenocarcinomatous ovarian tissues and normal and cancerous
fallopian tissue (3,4).
C© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.clinical.proteomics-journal.com
346 R. Longuespe´e et al. Proteomics Clin. Appl. 2013, 7, 337–354
Figure 5. Analysis of common proteins identified by LC-MS/MS between serous ovarian and tubal cancers. Venn diagram of protein IDs
from ovarian, tubal cancer, and normal ovarian tissues in the same patient case (A). Blast2Gowas then used to determine the gene ontology
of proteins with similar ID scores between the ovarian cancer and fallopian tube cancer tissues, and pie charts for cellular localization (B),
cellular processes (C), and molecular functions (D) were drawn.
numerous molecular actors, and a portion of these is in com-
mon between ovarian and tubal serous cancers.
The protein identification (ID) score was compared be-
tween the different tissue regions. The differential protein
IDs between ovarian cancer and benign tissues were selected
as proteins specifically implicated in the cancerous processes.
Someof these demonstrated highly similar ID scores between
ovarian cancer and fallopian tube cancer tissues. These pro-
teins were selected as proteins possibly implicated in ovarian
and tubal serous cancers processes.
The molecular function of each of the specific proteins
was determined using Blast2GO. Figure 5 shows pie charts
demonstrating the proteins’ cellular localization (Fig. 5B), the
biological processes in which they are involved (Fig. 5C) and
their molecular functions (Fig. 5D). In these representations,
we observed that the functions principally found in common
between ovarian and tubal cancer have been found in other
cancers. Therefore, we demonstrated that the major molec-
ular functions were related to molecular binding, with 35%
of protein binding, and metabolism (Fig. 5D). With regards
to cellular processes (Fig. 5C), the most represented corre-
sponds with well-known processes associated with cancer.
Processes such as growth, cell proliferation, cellular compo-
nent organization, biological adhesion, response to stimu-
lus and signaling and metabolic processes correspond with
classically described functions in tumorigenesis phenomena.
These elements provide an initial clue to the underlying
mechanisms related to these two cancers.
All of these proteins have been reported in a network rep-
resenting the functional interaction between these proteins
based on the String database interaction probability (Fig. 6).
In this network, a score based on the up- and downregu-
lation of each of the proteins in common with ovarian and
tubal cancers compared with the normal ovary is represented
by a color code; the green shade represents negative score
changes, and the red shade represents positive score changes.
Thus, we postulated that this change in the score ranking re-
flects expression changes, i.e. a negative score change repre-
sents downregulation (green), and positive score change rep-
resents upregulation (red). From this global network (Fig. 6A,
zoom in Supporting Information Fig. 3), subnetworks can be
extracted, corresponding to proteins with functions of inter-
est or related to physiopathological events. The first observa-
tion was that downregulation is predominant compared with
upregulation. The framed subnetwork represents proteins
associated with the NCI disease index (http://www.cancer.
gov/), and they were selected using the Cytoscape-
implemented Reactome FI plugin. Almost all of the selected
proteins were found to be involved in neoplasms (Fig. 6B). A
number of these proteins have also been found in female re-
productive systemneoplasms (Fig. 6C), particularly in ovarian
cancer neoplasms (Fig. 6D). Among the upregulated proteins,
we found chaperones, cell structure proteins, and proteins
involved in DNA replication. The downregulated proteins
correspond to other types of chaperone, adhesion, and struc-
tural proteins.
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Figure 6. Interaction networks of proteins common between serous ovarian and tubal cancers. Interactions were retrieved using gene
names in the STRING network database (A). A full network was then constructed using Cytoscape with relative expression data as the Id
mapper; the score based on the up and downregulation of each of the common proteins between ovarian and tubal cancers compared
with the normal ovary is represented by a color code with the green shade representing negative score changes and the red shade positive
score changes. The Reactome NCI plugin was then used to draw subnetworks for neoplastic proteins (B), female reproductive neoplasm
proteins (C) and ovarian cancer proteins (D). Blast2GO molecular functions were then used to represent networks for cell adhesion (E) and
innate immune system proteins (F).
From these data, the molecular functions of interest were
selected to construct subnetworks (Fig. 6, insets at right). We
decided to draw the networks of the proteins for which the
functions were mainly represented, namely cellular adhesion
(yellow-orange inset, Fig. 6E). Many of these proteins appear
downregulated. This corresponds to the metastatic behavior
of the cancerous cells [48]. Indeed, in a spatio-temporal con-
text, an EOC cell can detach from its tissue environment and
attach to a new site. During these events, the plasma mem-
brane of the cell loses its surface adhesion proteins for de-
tachment. These observations highlight the common process
mechanisms of ovarian and fallopian tube cancer tissues. Ac-
cording to the ectopic origin of ovarian cancer theory, a tubal
cancerous cell could detach from its tumor site and attach
in the ovarian environment. Another interesting molecular
function observed in this network representation is comple-
ment activation (purple inset, Fig. 6F).We also found proteins
associated with this function that was downregulated in the
ovarian and tubal cancer contexts. This downregulation is
also in agreement with previous discoveries. Previous work
has shown that there is an immunosuppression phenomenon
associated with ovarian cancer [48,49]. Here, complement ac-
tivation proteins, namely the complement proteins C3, C5,
C6, C7, C9, the complement component C8 gamma and beta
chains (C8B, C8G), the complement factor H, and the plasma
protease C1 inhibitor (SERPING1) (Supporting Information
Table 3) were downregulated in the ovarian cancer context.
Assuming that EOC has a Mu¨llerian origin, it is not difficult
to imagine that the suppression of the innate immune re-
sponse is mandatory for a tubal cell settling in the ovary. A
foreign cell could then act as an undetectable parasite in the
ovarian immune environment. This mechanism would also
be necessary for the evolution of these same cancerous cells
in the fallopian tube environment.
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Figure 7. Analysis of specific proteins from fallopian tube and serous ovarian cancers. From Blast2GO annotations, pie charts representing
the molecular functions of ovarian cancer proteins (A) and tubal cancer proteins (B), and the cellular processes of ovarian cancer proteins
(C) and tubal cancer proteins (D) were drawn. Using the Reactome NCI plugin, known ovarian cancer marker networks were traced from
the ovarian cancer (E) and tubal cancer networks (F).
To confirm the biological mechanistic found between
ovarian a tubals cancer, we aimed to evaluate the proteins
that were specifically found in both cancers but not in nor-
mal ovarian tissue. The distribution of the cellular processes
was almost the same. Moreover, we found an overexpression
of cytosqueletal proteins in ovarian cancer samples. We also
found immunoproteasome activators such as PA28 alpha,
which are known to be overexpressed and degraded in the
ovarian cancer context [29, 49].
In addition to the inspection of the common molecular
mechanisms of ovarian and tubal cancers, we examined the
specific molecular mechanisms of ovarian and tubal cancers.
Two arguments support this investigation. First, the analysis
of tubal cancer proteins may provide insight into the un-
derlying events in the fallopian tube environment that could
lead to the metastasis of cancerous cells in the ovarian envi-
ronment. In addition, investigation of specific serous ovarian
cancer proteinsmay elucidate themechanisms for cancer cell
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evolution in the ovarian environment. The second argument
is that this analysis may provide a list of highly specific
biomarkers for each cancer. Indeed, this specific workflow
allows for the comparison of the tissue types in their anatom-
ical context. Each protein then is found in only one tissue
and not in the other two. The confidence of this specificity is
even higher because we compared gynecological tissues with
each other. Indeed, it is difficult to attribute a gynecological
disease biomarker to a specific organ.
We first determined the gene ontology of each protein
specifically identified in serous or ovarian tissues and evalu-
ated their molecular function. Figure 7A, B, C, and D shows
themolecular functions and cellular processes of serous ovar-
ian cancer and the molecular functions and the cellular pro-
cesses of tubal cancer.We found that themolecular functions
were not drastically different between the two tissues. The rel-
ative distributions of the functions were similar between the
two cancers. This suggests that, although different proteins
are implicated in fallopian tube tumorigenesis, the same bi-
ological mechanisms contribute to both neoplasms.
For example, molecular binding was highly represented
in the two tissues. However, other molecular functions were
listed for ovarian cancer including transmembrane transport
and the peptidase function. Actin modeling, proliferation,
and intercellular adhesion are the primary functions found
in serous cancer. Here again, the most represented function
was molecular binding.
However, by close inspection of the nature of the proteins
specifically identified in serous ovarian cancer (Supporting
Information Table 1), we observed that the proteins bearing
binding functions were drastically different from the proteins
found in common between ovarian and tubal cancer. Indeed,
we found that the adhesion proteins overexpressed in ovar-
ian tissue were proteins corresponding to epithelial differ-
entiation. For example, cell–cell adhesion proteins, cell–cell
adherent junction proteins, homophilic, and homotypic cell
adhesion proteins were highly represented functions in this
histological context. Some proteins implicated in cellular ad-
hesion with the extracellular matrix were also found. The
second striking observation was the high content of proteins
implicated in cellular proliferation. Finally, many proteins
associated with actin modeling appeared as an important
overrepresented function among those proteins. These ob-
servations provide insights into the specific mechanisms we
found in ovarian cancers. In fact, serous ovarian carcinogen-
esis appears to be controlled by highly specific mechanisms.
These mechanisms may consist of the acquisition of epithe-
lial characteristics combined with a great modeling of the cell
shape and a greater proliferation potential. Other represented
proteins are implicated in metabolism, HSP binding, lipid
transport, and catabolism, and MAPK network activation. All
of these events are in agreement with previous findings in
ovarian cancer research [48].
We also used the Reactome NCI plugin to determine
whether the proteins were previously characterized in ovar-
ian neoplasms. The network of these proteins is presented in
Fig. 7E (Supporting Information Table 4). Among these,
we found the GTPases KRas [50] and NRas [51], mitogen-
activated protein kinase 1 [52, 53], and receptor tyrosine-
protein kinase erbB-2 [54, 55], which are involved in the epi-
dermal growth factor receptor signaling pathway that greatly
promotes ovarian cancer [56–58], resulting in cancer progres-
sion. Focal adhesion kinase 1 [59] is involved is the VEGF
(vascular endothelial growth factor) receptor pathway, which
promotes angiogenesis and the integrin pathway and induces
the mitogen-activated protein kinase pathway [53], resulting
in cancer progression. Fibronectin [60] is the extracellular
component that activates the integrin pathway. The integrin
pathway also induces actin polymerization for cellular re-
modeling [61]. In addition, metastasis-associated protein is
involved in activating the p53 pathway [62].
Supporting Information Table 1 lists the proteins specifi-
cally identified in serous ovarian cancer, from the highest to
lowest score. In this table, we determined that themost preva-
lent proteins corresponded to proteins associatedwith cellular
shape changes [63], including cytoskeletal proteins, namely
actin, beta actin like protein and microtubule-associated pro-
teins. Proteins associated with nuclear modeling constituted
another group ofwell-represented proteins, includinghistone
H2B, histone H3, and heterochromatin protein 1-binding
protein. The epigenetic modification of histones results in
the repression of some genes and tumorigenesis events [64].
Among the highest scoring proteins, we also found those
implicated in metabolism such as transketolase [65], which
is implicated in the pentose-phosphate pathway that is of-
ten used in metastatic processes [48]. We also found proteins
involved in glycolysis, which is another preferred metabolic
pathway [66], including 6-phosphofructokinase and enolase.
As previously mentioned, proteins involved in cell–cell inter-
actions are represented, including zyxin [67] and desmoglein.
Finally, we found that the majority of proteins implicated in
RNA and protein synthesis were among the highest scor-
ing. Among these proteins, we found heterogeneous nu-
clear ribonucleoproteins, ribosome-binding protein, eukary-
otic translation initiation factor, protein disulfide-isomerase,
60 kDa SS-A/Ro ribonucleoprotein, and regulation of nuclear
pre-mRNA domain-containing protein. All of these proteins
had high scores in this analysis and may be considered for
further analyses and validation by other methods using a
large patients cohort. In this study, we determined the most
important proteins specifically expressed in serous ovarian
cancer.
We then investigated the specific tubal cancer biomarkers.
The aim of this part of the study was to evaluate the relevance
of the ovarian biomarkers for serous ovarian cancers. In-
deed, if the ovarian cancer origin theory is valid, then tubal
precursor markers may be appropriate for screening large co-
horts of patients for the diagnosis of highly prevalent serous
ovarian cancer. To do so, we used the Reactome NCI plugin
to determine whether biomarkers initially discovered in the
ovarian cancer context were expressed in fallopian tube tis-
sues (Fig. 7F, Supporting Information Table 4). We observed
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Clinical Relevance
With about 22 000 cases estimated in 2012 in the
United States and 15 500 deaths, ovarian cancer is
the fifth deadliest cancer among American women.
Although some progress have been made by pro-
longing remission by the combination of aggres-
sive surgery and chemotherapy, outcome for patients
with ovarian cancer remains poor, with 5-year sur-
vival being about 30%. Possible reasons for the slow
progress in the efficiency of treatment are the lack
of early screening methods and the fact until re-
cently that ovarian cancers have been considered
as a unique entity. In fact, ovarian cancer is a gen-
eral term for a series of molecular and aetiologi-
cally distinct diseases that share only an anatomical
location. A better understanding of the molecular
mechanisms underlying ovarian will permit several
improvement of management of ovarian cancer.
First, knowledge of the origin of the different ovar-
ian cancer permits well-fitted prophylactic measures
(e.g. salpingectomy for high-grade serous ovarian
cancer, ablation of endometriotic lesions for clear
cell ovarian carcinoma). Second, the description of
molecular specificity of the proteins of each subtype
will permit definition of early biomarkers, useful for
early diagnosis. Third, molecular insights will iden-
tify therapeutic targets. Fourth, clinical trials should
no longer aggregate the various ovarian types. Clin-
ical reporting and scientific publications should use
standardized terms for these entities. Fifth, improved
experimental models must reflect the various origi-
nating cells and underlying genomic events driving
each subtype.
that highly scoring proteins that were previously assigned to
ovarian neoplasm were found in the fallopian tube tissue.
This finding is the first clue that some biomarkers normally
found in an ovarian cancer context may actually be tubal can-
cer biomarkers. Among these proteins, we found Fibronectin
1,which is implicated in the integrin pathway for actin remod-
eling [60]; cell division control protein 42, which is involved
in cell migration [68]; the glycolysis enzyme gamma-enolase;
high-mobility group protein 1 [69], which is involved in the
facilitation of transcription, replication, recombination, and
DNA repair. We also found some cell–cell junction proteins
such as junction plakoglobin and alpha catenin a1 because
tubal cancer is also an epithelial cancer; and serine/threonine-
protein kinase PAK 1 [70] and integrin-linked protein kinase,
which are involved in cytoskeleton remodeling [71].
This network is striking evidence that biomarkers initially
found in the ovarian cancer context are also fallopian tube
cancer biomarkers. This finding is reinforced by the fact
that the Reactome NCI Plugin did not allow us to find tubal
cancer biomarkers in the tubal cancer environment. Ovarian
and tubal cancers evidently share biological functions
in their development. However, the anatomical context
provides a more accurate insight of the biomarkers for each
gynecological disease.
Finally, we closely investigated the biological relevance
of the highest scoring biomarkers in the fallopian tube en-
vironment to highlight the gynecological markers that the
Reactome NCI Plugin may have missed.
Among all of the high scoring proteins found in the tubal
tumoral environment, the most striking is periostin. This
protein has been reported to be present in the environment
of many cancer cells types. Periostin is a component of the
extracellular matrix, and in cancer, it acts as a ligand for
alpha-V/beta-3 and alpha-V/beta-5 integrins to support the
adhesion and migration of epithelial cells [72]. The binding
of this ligand also promotes the recruitment of the epidermal
growth factor receptor and the activation of the Akt/PKB- and
FAK-mediated signaling pathways [71]. Periostin-activated
signaling pathways also promote cellular survival, angiogen-
esis, and resistance to hypoxia-induced cell death. In ovarian
cancer, periostin promotes ovarian cancer angiogenesis and
metastasis [72,73]. In this particular case, we found periostin
specifically expressed in the fallopian tube cancer environ-
ment and not in that of ovarian cancer. This is a highly im-
portant point for the understanding of the relevance of the
adapted workflow. This specific approach, relying on tissue
proteomics in an anatomical context, allowed us to determine
that periostin was a tubal cancer protein that was not present
in ovarian cancer. This also allows us to identify another re-
sponse element to the question of ovarian cancer cellular
origin. Here, we can speculate that periostin, which is highly
expressed in tubal cancer, may induce the metastasis of fal-
lopian tube cancer cells and promote their metastasis to a
host tissue, which includes the ovary.
Osteopontin is another biomarker of the same type that
promotes cell migration via integrin binding, and it has been
previously found in epithelial ovarian cancers and was se-
lected together with five other biomarkers for themultiplexed
screening of epithelial ovarian cancers [74].
In this manner, ovarian serous cancers may develop af-
ter early metastasis events in the fallopian tube context from
tubal cancer cells settling in the ovary. This theory is in agree-
ment with the relative anatomical position of the fallopian
tubes and the ovaries in the gynecological tracts. The fallop-
ian tubes and the ovaries are physiologically closely related.
For example, during reproduction events after ovulation, the
female gamete migrates from the ovary to the endometrium
through the fallopian tube. From this point of view, it is not
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surprising that the preferred hosting site for amigrating tubal
cancer cell would be the ovary.
It is now possible to link the events that we observed that
are shared by the fallopian tubes and ovaries and specific ovar-
ian cancer events. We found that the events shared between
ovarian and fallopian tube cancers consisted of the down-
regulation of many proteins. Assuming that a serous ovarian
cancer could be derived froma fallopian tube cancerous cell, it
appears that in both cases, this cellmay need to act as amolec-
ular phantom in its anatomical context, which results from
the suppression of immuneproteins in the cancerous context.
The adhesion of the cell to the extracellular matrix must then
be suppressed for detachment for its tumoral context. This
detachment would be promoted by extracellular matrix ele-
ments. In the ovarian environment, cell proliferation greatly
increases. In addition, the cell may undergomany changes to
acquire epithelial characteristics. This event is transduced by
an important remodeling of the actin network of the cell and
the expression of proteinsmostly involved in cell–cell interac-
tions. All of the proteins specifically found in the ovarian can-
cer context may represent pathological biomarkers. Indeed,
membrane proteins that are in close contact with the extracel-
lular milieu, which could easily be found in circulating fluids,
must have a particular role in the transformation process.
We also demonstrated that some ovarian cancer biomark-
ers are actually fallopian tube cancer biomarkers. This discov-
ery highlights the relevance of the anatomical context in the
biomarkers research field. At the same time, this discovery
suggests newmethods for investigating the clinical screening
of ovarian cancer.
4 Concluding remarks
Many questions remain regarding the origin of EOC and its
mechanisms of progression. The emergence of proteomic
technologies that identify potential biomarkers in body fluids
and tissues allows biologists and clinicians to access patho-
logical analysis on the molecular scale.
Here, we proposed a two-step strategy for the study of spe-
cific proteins in their histological context. The first step is a
quick examination of the molecular profiles found in tissues
that are of a different nature. The PCA calculation is based
on a global comparison ofmultidimensional data.We applied
these analyses to spectra groups using the relative intensities
of the detected peaks in tissue sections. This experiment is a
quick way to provide the complete molecular content trends
of the histological regions of interest on a single or a few biop-
sied sections. PCA was used for the comparison of tissues in
the same patient to avoid interpatient tissue variability. We
speculated that the analysis of a small number of tissues may
gain confidence when the patient is considered as the control
in the experiment. The 2D representations provided by PCA
allowed us to classify these in a way that our findings sup-
port the Mu¨llerian origin of endometrioid and serous cancer
hypothesis.
The second step consisted of a deeper investigation of the
molecular actors in the tissues of interest. To do so, we per-
formed a shotgun proteomics analysis of the tryptic digests
analyzed on tissues with the MALDI source. The subsequent
analyses using Blast2GO and Cytoscape softwares gave us a
global view of the potential biological events that may occur
during serous cancer development. If we assume that serous
epithelial ovarian cancers originate from a fallopian tube can-
cerous precursor, then cell detachmentmechanisms from the
tumor site may be involved as an immunosuppressionmech-
anism for a cell that is considered a foreign element in the
physiological context. In the ovarian environment, additional
specific events may occur. The newly settled and undifferen-
tiated cell may differentiate into an epithelial cell to form an
epithelial cancer in the ovarian host site.
This type of experiment can provide important insights
into the histological specificity of the proteins of each pathol-
ogy. We introduce a new concept that consists of provid-
ing new evidence for a clinical problem while assessing the
molecular specificity of the pathological proteins. Based on
the relative scores of the proteins found in different tissues,
we were able to assess the relative specificity of the proteins in
each tissue. We then provided the first proteomic insight into
the degree of similarity of the serous ovarian cancer tissues
with its possibly related Mu¨llerian tissue. This comparison
allowed us to elucidate the possible molecular mechanisms
found in the appearance of ovarian cancer and its develop-
ment.
Determining the specific serous epithelial ovarian cancer
markers is only possible using this specific tissue profiling
workflow. Thismay be considered for specific tissue biomark-
ers studies. The proteins upregulated in each tissue may be
selected for their specificity against two or more tissues from
the same patient. Indeed, the clinical value of a biomarker
that is useable for a diagnostic test is its specificity for one
cancer type as opposed to another. Here, we propose a list
of specific serous ovarian cancer proteins that are found in
their anatomical context and guaranteed to be absent in nor-
mal ovarian tissue and another type of gynecological cancer
from the same patient, i.e. the fallopian tube. Thus, these
proteins are specific to the cancerous pathological status and
are specific for the ovary as opposed to other gynecologic
neoplasms.
The scope of this type of analysis is to evaluate the most
appropriate biomarkers for serous ovarian cancer. If the fal-
lopian tube is the cause of ovarian cancer, a large campaign
identifying the fallopian tube cancer biomarkers may be per-
formed. This may provide an insight into the early develop-
ment of this specific neoplasm and identify the precise time
when radical fimbriectomy may be performed for at-risk or
even nonsuspecting patients.
To definitively validate the hypotheses and biomarkers
found, it will be necessary to repeat this experiment in a large
cohort of tissues and interpret the results using statistical
analyses. However, using the same patient for a comparison
analysis is an excellent internal control for the experiment.
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At this time, we speculate that the observations made after
this study may be the cornerstone of the Mu¨llerian origin of
serous ovarian cancer theory.
In conclusion, this workflow is an example of the poten-
tial of themass spectrometric profilingmethod for biomarker
research and for specific clinical application. We have been
able to prove the feasibility of thismethodwhile providing the
first proteomic evidence of the potential tubal origin of serous
ovarian cancer. We also introduced a new research method
for the investigation of gynecological cancer biomarkers. On-
tissue proteomics allowed us to determine that ovarian can-
cer biomarkers may actually derive from fallopian tube can-
cer precursors; it may then be relevant to compare whether
biomarkers found in fallopian tube cancers have good pre-
dictive values for ovarian cancer screening in large patient
cohorts. This type of investigation may be highly relevant for
the early detection of ovarian cancers.
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